Meningitis
📧 Sign up to get email alerts when something new happens for Meningitis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-18EMA Authorised: MenQuadfi (Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid) — Sanofi Winthrop Industrie
EMA has authorised MenQuadfi, a meningococcal vaccine combination covering groups A, C, W-135, and Y (tetanus toxoid-conjugated), for mening…
-
EMA approval · 2026-07-10EMA Authorised: Menveo (meningococcal group A, C, W-135 and Y conjugate vaccine) — GSK Vaccines S.r.l.
The European Medicines Agency has authorised Menveo, a meningococcal group A, C, W-135 and Y conjugate vaccine by GSK Vaccines S.r.l., for i…
-
CLINICAL_TRIALS trial_result · 2026-04-21Clinical Trial Update: A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old) [Phase 3]
Phase 3 trial evaluating the immune response and safety of the RmenB + OMV NZ meningitis vaccine in primed healthy participants aged 10-20 h…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents [Phase 2]
Phase 2 clinical trial update evaluating safety, tolerability, and immunogenicity of the MenABCWY vaccine administered on different dosing s…
-
FDA approval · 2026-04-07FDA Approved: CEFEPIME HYDROCHLORIDE AND DEXTROSE — Supplemental Application (B. Braun Medical Inc.)
FDA approved a supplemental application from B. Braun Medical Inc. for Cefepime hydrochloride and dextrose, adding this formulation under th…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years [Phase 3]
A Phase 3 clinical trial evaluating Sinovac's Group ACYW135 meningococcal conjugate vaccine in children aged 2-6 years; the study is current…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months [Phase 3]
Phase 3 study evaluating Group ACYW135 meningococcal conjugate vaccine in children aged 12-23 months; the trial is currently not yet recruit…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months [Phase 3]
Phase III trial of a meningococcal conjugate vaccine (groups A, C, Y, W-135) in infants aged 3-5 months, status not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months [Phase 3]
Phase 3 clinical trial update for a meningococcal conjugate vaccine (Group ACYW135) in infants aged 6-11 months, with the study currently no…
-
FDA approval · 2026-03-11FDA Approved: MEROPENEM — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for Meropenem by Sandoz Inc, resulting in updated regulatory status for the product.
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: Clinical Performance of QIAstat-Dx® Meningitis/Encephalitis (ME) Panel Plus
This update describes the clinical performance evaluation of the QIAstat-Dx ME Panel Plus for meningitis and encephalitis. The trial status …
-
CLINICAL_TRIALS trial_result · 2026-03-04Clinical Trial Update: Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) [Phase 4]
Status update for a Phase IV trial evaluating the immunogenicity of the ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Prediction of Infectious Agents in the Biofire® FilmArray bioMérieux Meningitis/Encephalitis Panel Based on Clinical Syndrome and Cerebrospinal Fluid Parameters: a Diagnostic Stewardship Proposal. [NA]
This is a diagnostic stewardship research proposal to predict infectious agents in the BioFire FilmArray Meningitis/Encephalitis Panel using…
-
CLINICAL_TRIALS trial_result · 2026-02-12Clinical Trial Update: A Study Assessing Colonisation & Immunogenicity After Nasal Inoculation With N. Lactamica and Eradication on Day 4 or 14 [NA]
A study evaluating nasal inoculation with Neisseria lactamica to assess colonization and immunogenicity was terminated. Results were posted …
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Optic Nerve Ultrasound for Assessing Cerebral Inflammation and Intracranial Hypertension in Cerebral Pathologies
Clinical trial investigating optic nerve ultrasound as a noninvasive method to assess cerebral inflammation and intracranial hypertension ac…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Meningitis: Burden, Causes, Screening and Prevention in Rural Northern Uganda [NA]
A clinical trial update describing a study on meningitis burden, causes, screening, and prevention in rural Northern Uganda, currently in re…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: Neuroendoscopic Surgery With Ommaya Reservoir Implantation vs. Burr Hole Drainage for Infantile Postmeningitis Subdural Lesions: Superior Efficacy, Critical Impact of Surgical Timing, and Pathogenic Bacteria as Risk Factors for Progression
This clinical trial compares neuroendoscopic surgery with Ommaya reservoir implantation to burr hole drainage for infantile postmeningitis s…
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine [Phase 1]
This is a Phase 1 clinical trial evaluating an adsorbed, acellular pertussis vaccine component combined with Hib and ACWY meningococcal comp…
-
EMA approval · 2025-12-17EMA Authorised: Trumenba (Neisseria meningitidis serogroup B fHbp (recombinant lipidated fHbp (factor H binding protein)) subfamily A; Neisseria meningitidis serogroup B fHbp (recombinant lipidated fHbp (factor H binding protein)) subfamily B) — Pfizer Europe MA EEIG
The EMA has authorised Trumenba, a vaccine against meningococcal disease caused by Neisseria meningitidis serogroup B, for use in Europe.
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Evolving Diagnostic Approaches to Undocumented Lymphocytic Meningitis and Meningoencephalitis
The document reports a clinical trial update on evolving diagnostic approaches to undocumented lymphocytic meningitis and meningoencephaliti…
-
CLINICAL_TRIALS trial_result · 2025-09-12Clinical Trial Update: Primary Immunodeficiencies and Obstetrical Neuraxial Anaesthesia
This completed clinical trial evaluated safety issues related to obstetrical neuraxial anesthesia in patients with primary immunodeficiencie…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: Diagnostics and Surveillance of Acute Meningo-encephalitis Among Children in Cambodia With a Focus on Japanese Encephalitis Virus
This clinical trial update describes a protocol in Cambodian children to diagnose and surveil acute meningitis/encephalitis with a focus on …
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: Investigation of the Role of Inflammatory Markers in the Early Detection of Cerebral Vasospasm, Delayed Cerebral Ischemia, and Meningitis Associated With External Cerebrospinal Fluid Drainage After Non-Traumatic Subarachnoid Hemorrhage - A Prospective Case-Control Study
This prospective case-control study assesses whether inflammatory markers can enable early detection of cerebral vasospasm, delayed cerebral…
-
EMA approval · 2025-08-01EMA Authorised: Bexsero (outer membrane vesicles from neisseria meningitidis group b (strain nz 98/254);recombinant Neisseria meningitidis group B fHbp fusion protein;recombinant Neisseria meningitidis group B NadA protein;recombinant Neisseria meningitidis group B NHBA fusion protein) — GSK Vaccines S.r.l.
The European Medicines Agency authorised Bexsero, a meningococcal group B vaccine produced by GSK Vaccines S.r.l., for use in Europe. The va…
-
CLINICAL_TRIALS research · 2025-07-30Clinical Trial Update: Bedside Ultrasound on the Effectiveness of Lumbar Puncture in Children. [NA]
A recruiting clinical study at the Medical University of Warsaw is evaluating whether bedside ultrasound improves the effectiveness of lumba…